SAN JOSE, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nutanix, Inc. ("Nutanix") NTNX , a leader in hybrid multicloud computing, today announced its intention to offer, subject to market conditions and other factors, $750 million aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Nutanix also expects to grant the initial purchasers of the notes an option to purchase up to an additional $112.5 million aggregate principal amount of the notes within a 13-day period from, and including, the initial issuance date of the notes. The notes will be unsecured senior obligations of Nutanix. Interest will be payable semi-annually in arrears. The notes will mature on December 15, 2029, unless earlier converted, redeemed, or repurchased. The notes will be convertible at the option of holders, subject to certain conditions and during certain periods. Upon conversion, the notes may be settled in cash, shares of Nutanix's Class A common stock or a combination of cash and shares of Nutanix's Class A common stock, at Nutanix's election. The interest rate, initial conversion rate and other terms of the notes are to be determined at the time of the pricing of the offering. Nutanix intends to use the net proceeds from the offering to (i) repurchase a portion of its outstanding 0.25% Convertible Senior Notes due 2027 (the "2027 notes") concurrently with the pricing of the offering in separate and privately negotiated transactions with certain holders of its 2027 notes (the "concurrent note repurchases") effected through one of the initial purchasers of the notes or its affiliate, acting as Nutanix's agent, and (ii) repurchase up to $200.0 million of shares of Nutanix's Class A common stock in privately negotiated transactions with institutional investors effected through one of the initial purchasers of the notes or its affiliate, acting as Nutanix's agent, at a price per share equal to the last reported sale price of Nutanix's Class A common stock on the Nasdaq Global Select Market on the date of the pricing of the notes (the "Share Repurchase"). Any such Share Repurchase would not reduce the amount available for future repurchases under Nutanix's existing share repurchase program. Nutanix intends to use the remaining net proceeds from the offering for general corporate purposes, including working capital, capital expenditures and potential acquisitions. From time to time, Nutanix evaluates potential acquisitions of businesses, technologies or products. Currently, however, Nutanix does not have any understandings or agreements with respect to any acquisitions. The terms of the concurrent note repurchases are anticipated to be individually negotiated with each holder of the 2027 notes participating in the concurrent note repurchases, and will depend on several factors, including the market price of Nutanix's Class A common stock and the trading price of the 2027 notes at the time of each such concurrent note repurchase. Certain holders of any 2027 notes that Nutanix agrees to repurchase may have hedged their equity price risk with respect to such 2027 notes and may, concurrently with the pricing of the notes, unwind all or part of their hedge positions by buying Nutanix's Class A common stock and/or entering into or unwinding various derivative transactions with respect to Nutanix's Class A common stock. Any repurchase of the 2027 notes, and the potential related market activities by holders of the 2027 notes participating in the concurrent note repurchases, together with the repurchase by Nutanix of any of its Class A common stock concurrently with the pricing of the notes, could increase (or reduce the size of any decrease in) the market price of Nutanix's Class A common stock, which may affect the trading price of the notes at that time and the initial conversion price of the notes. Nutanix cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or its Class A common stock. No assurance can be given as to how much, if any, of the 2027 notes or the Class A common stock will be repurchased or the terms on which they will be repurchased. Neither the notes nor the shares of Nutanix's Class A common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, such registration requirements. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. About Nutanix Nutanix is a global leader in cloud software, offering organizations a single platform for running applications and managing data, anywhere. With Nutanix, companies can reduce complexity and simplify operations, freeing them to focus on their business outcomes. Building on its legacy as the pioneer of hyperconverged infrastructure, Nutanix is trusted by companies worldwide to power hybrid multicloud environments consistently, simply, and cost-effectively. Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Nutanix's financing plans, Nutanix's ability to complete the offering, the timing and size of the offering, the concurrent note repurchases and the Share Repurchase, Nutanix's intended use of the net proceeds of the offering. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether Nutanix will be able to consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions with respect to the offering of the notes, prevailing market conditions, the anticipated use of the net proceeds of the offering of the notes, which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Forward-looking statements may be identified by the use of the words "may," "will," "expect," "intend," and other similar expressions. These forward-looking statements are based on estimates and assumptions by Nutanix's management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. Actual results may differ materially from those anticipated or predicted by Nutanix's forward-looking statements. All forward-looking statements are subject to other risks detailed in Nutanix's Annual Report on Form 10-K for the fiscal year ended July 31, 2024, and the risks discussed in Nutanix's other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Nutanix undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof, except as required by applicable law. © 2024 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or unregistered trademarks of Nutanix, Inc. ("Nutanix") in the United States and other countries. Other brand names or marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This press release is for informational purposes only and nothing herein constitutes a warranty or other binding commitment by Nutanix. Investor Contact: Richard Valera ir@nutanix.com Media Contact: Lia Bigano pr@nutanix.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Wade Taylor IV helps No. 22 Texas A&M get by Texas Tech
online gambling articles
。
A fugitive gains fame in New Orleans eluding dart guns and netsNEW YORK — Half of the claims for public matching funds that Mayor Eric Adams’ reelection campaign submitted in the most recent reporting period were deemed “invalid” by the city’s Campaign Finance Board, the highest rejection rate the mayor’s team has faced to date, records obtained by the Daily News show. The rejections come at a critical time for Adams’ campaign. The CFB is weighing whether to give Adams’ 2025 campaign any matching funds at all amid his federal indictment on charges alleging he took illegal political donations and bribes, mostly from Turkish government operatives. A decision by the board to withhold public funds from Adams, who has pleaded not guilty, could deal a serious blow, with millions of dollars at stake as he faces seven challengers in June’s Democratic mayoral primary . The board — which is set to announce Monday whether to award Adams matching funds — has said it’s considering the allegations in his indictment as part of its final decision, on top of various other factors required under CFB rules, like claim denial rates. The new records obtained by The News via a Freedom of Information Law request show Adams’ 2025 campaign submitted a total of 268 donations for matching funds in the latest reporting period, which spanned from July 12 through Oct. 7. Of them, 134 — 50% of all claims the campaign submitted in the period — were found by the CFB to be “invalid,” the records show. The reasons for the rejections included contributions in question not being “timely reported,” no “backup documentation” being provided by Adams’ campaign and donors being listed in the city’s Doing Business database . Under the matching funds program, mayoral campaigns get eligible contributions from city residents matched by the CFB at an 8-to-1 rate up to $250. The Adams campaign’s 134 “invalid” claims total $31,051, meaning they could be worth a combined $248,408 if matched with public funds. The 50% denial rate is the highest Adams has seen in a reporting period since he started raising cash for his reelection run shortly after taking office in 2022. The second highest was the 25% of matching claims denied in the first period of the 2025 cycle, which ran between Jan. 15, 2022 and July 11, 2022, records show. In a Nov. 12 letter to Sharon Adams, the mayor’s campaign treasurer, CFB auditing director Danielle Willemin wrote the Adams team has until Jan. 15 to respond to the latest findings if they believe some of the claims are valid. However, Willemin noted in the letter that Adams’ team would need to respond by Nov. 22 if it hoped to cure the claims in time for them to be included in next week’s public funds payout, the first of the 2025 cycle. The records obtained by The News show the campaign didn’t file any response by Nov. 22. Vito Pitta, Adams’ campaign attorney, didn’t respond to questions about the CFB findings this week. Besides the latest reporting window, Adams still has 458 “invalid” claims from the five previous 2025 cycle reporting periods that haven’t been cured by his campaign to date, the records show. Those outstanding claims are worth $108,433, giving them a total matched value of $876,464, the records say. Some matching fund claim denials are common, said Marty Connor, a former state senator and veteran New York campaign finance compliance lawyer. However, Connor said Adams’ 50% denial rate stands out. “That’s high comparatively,” Connor said, adding rates exceeding roughly 20% are outside the norm. The 50% denial rate came in a period in which Adams’ reelection campaign received $146,151 in donations, the lowest fundraising stretch he has had since becoming mayor. Amid the cash dip, Adams’ team said it had essentially ceased fundraising for his reelection, arguing he had hit the campaign spending cap if expected matching funds are factored in. The drop also came as Adams was focusing on raising money for his legal defense fund , which he’s using to cover attorney fees he’s racking up to defend himself in his corruption case prosecuted by the Manhattan U.S. attorney’s office. The CFB has dinged Adams’ political operation for alleged bookkeeping errors before , including compiling a draft audit earlier this year identifying $2.3 million in improperly documented spending by his 2021 campaign. In total, Adams’ 2025 campaign has submitted 1,747 matching claims deemed valid on initial inspection by the CFB, totaling $404,142, records show. With matching funds, those donations are worth a cumulative $3.2 million if CFB ultimately opts to give Adams public cash. ©2024 New York Daily News. Visit nydailynews.com . Distributed by Tribune Content Agency, LLC.US President Joe Biden on Sunday said deposed Syrian leader Bashar al-Assad should be "held accountable" but called the nation's political upheaval a "historic opportunity" for Syrians to rebuild their country. In the first full US reaction to Assad's overthrow by an Islamist-led coalition of rebel factions, Biden also warned that Washington will "remain vigilant" against the emergence of terrorist groups, announcing that US forces had just conducted fresh strikes against militants from the Islamic State organization. "The fall of the regime is a fundamental act of justice," Biden said, speaking from the White House. "It's a moment of historic opportunity for the long-suffering people of Syria." Asked by reporters what should happen to the deposed president, who reportedly has fled to Moscow, Biden said that "Assad should be held accountable." Biden -- set to step down in January and make way for Republican Donald Trump's return to power -- said Washington will assist Syrians in rebuilding. "We will engage with all Syrian groups, including within the process led by the United Nations, to establish a transition away from the Assad regime toward independent, sovereign" Syria "with a new constitution," he said. However, Biden cautioned that hardline Islamist groups within the victorious rebel alliance will be under scrutiny. "Some of the rebel groups that took down Assad have their own grim record of terrorism and human right abuses," Biden said. The United States had "taken note" of recent statements by rebels suggesting they had since moderated, he said, but cautioned: "We will assess not just their words, but their actions." Biden said Washington is "clear eyed" that the Islamic State extremist group, often known as ISIS, "will try to take advantage of any vacuum to reestablish" itself in Syria. "We will not let that happen," he said, adding that on Sunday alone, US forces had conducted strikes against ISIS inside Syria. The US military said the strikes were conducted by warplanes against Islamic State operatives and camps. Strikes were carried out against "over 75 targets using multiple US Air Force assets, including B-52s, F-15s, and A-10s," the US Central Command said on social media. Earlier, Biden met with his national security team at the White House to discuss the crisis. Assad's reported departure comes less than two weeks after the Islamist Hayat Tahrir al-Sham (HTS) group challenged more than five decades of Assad family rule with a lightning rebel offensive that broke long-frozen frontlines in Syria's civil war. They announced Sunday they had taken the capital Damascus and that Assad had fled, prompting celebrations nationwide and a ransacking of Assad's luxurious home. A Kremlin source told Russian news agencies that the deposed leader was now in Moscow, along with his family. The US military has around 900 troops in Syria and 2,500 in Iraq as part of the international coalition established in 2014 to help combat the Islamic State jihadist group. It has regularly struck targets in the country including those linked to Iranian-backed militias. Tehran was a major backer of Assad's government. Biden also confirmed US authorities believe the American journalist Austin Tice, who was abducted in Syria in 2012, still lives. "We believe he's alive," Biden said, but the US has yet "to identify where he is." bur-sms/mlm
BOSTON--(BUSINESS WIRE)--Dec 8, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVYTM (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additional evidence of the benefits of eradicating transfusion requirements for people with transfusion-dependent beta thalassemia and vaso-occlusive crises for those with sickle cell disease,” said Franco Locatelli, M.D., Ph.D., Professor of Pediatrics at the Catholic University of the Sacred Heart of Rome, Director of the Department of Pediatric Hematology and Oncology at Bambino Gesù Children’s Hospital, Chair of Vertex’s TDT Program Steering Committee, and Presenting Author of the CASGEVY clinical data at ASH. “With median follow-up around three years there is strong evidence for the durability of these beneficial effects following treatment with CASGEVY.” “CASGEVY is changing the outlook for people living with sickle cell disease and beta thalassemia, with these data reinforcing the immense clinical value a durable one-time therapy can provide to patients,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “We have a strong commitment to build on our progress in bringing CASGEVY to patients around the world.” New long-term follow-up data presented from the CASGEVY trials Vertex had seven abstracts accepted at the ASH annual meeting as outlined below: Progress in bringing CASGEVY to patients around the world CASGEVY is approved for both SCD and TDT in the U.S., the European Union, Great Britain, Canada, Switzerland, Bahrain and the Kingdom of Saudi Arabia, and Vertex plans to make submissions in the United Arab Emirates and Kuwait. More than 45 authorized treatment centers have been activated globally to support the delivery of CASGEVY, and more than 40 patients have had a first cell collection. Vertex is continuing to work with reimbursement authorities to secure sustainable access for patients. Through this work, Vertex has agreements to provide CASGEVY in multiple countries, including the U.S., England (TDT), Austria, Bahrain and the Kingdom of Saudi Arabia, and continues to make strong progress in others, including positive Health Technology Assessments (HTAs) in Canada for both diseases and advancing access negotiations for SCD patients in England. In the U.S., Vertex recently secured an industry-first, voluntary agreement with the Centers for Medicare & Medicaid Services (CMS) on a single outcomes-based arrangement available to all state Medicaid programs to ensure broad and equitable access to CASGEVY. To support this progress on patient access and growing patient demand, Vertex has received approval for a third manufacturing facility for CASGEVY with our partner Lonza. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive and life-shortening disease. SCD patients report health-related quality of life scores well below the general population, and the lifetime health care costs in the U.S. of managing SCD for patients with recurrent VOCs is estimated between $4 and $6 million. SCD is an inherited blood disorder that affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or “sickled” red blood cells. The clinical hallmark of SCD is VOCs, which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires a lifetime of treatment and results in a reduced life expectancy. In the U.S., the median age of death for patients living with SCD is approximately 45 years. A cure for SCD today is a stem cell transplant from a matched donor, but this option is only available to a small fraction of patients living with SCD because of the lack of available donors. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and the lifetime health care costs in the U.S. of managing TDT are estimated between $5 and $5.7 million. TDT requires frequent blood transfusions and iron chelation therapy throughout a person’s life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. In the U.S., the median age of death for patients living with TDT is 37 years. Stem cell transplant from a matched donor is a curative option but is only available to a small fraction of people living with TDT because of the lack of available donors. About CASGEVYTM (exagamglogene autotemcel [exa-cel]) CASGEVYTM is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CASGEVY (exagamglogene autotemcel) WHAT IS CASGEVY? CASGEVY is a one-time therapy used to treat people aged 12 years and older with: • sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs • beta thalassemia (β-thalassemia) who need regular blood transfusions CASGEVY is made specifically for each patient, using the patient’s own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF). Having more HbF increases overall hemoglobin levels and has been shown to improve the production and function of red blood cells. This can eliminate VOCs in people with sickle cell disease and eliminate the need for regular blood transfusions in people with beta thalassemia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about CASGEVY? After treatment with CASGEVY, you will have fewer blood cells for a while until CASGEVY takes hold (engrafts) into your bone marrow. This includes low levels of platelets (cells that usually help the blood to clot) and white blood cells (cells that usually fight infections). Your doctor will monitor this and give you treatment as required. The doctor will tell you when blood cell levels return to safe levels. You may experience side effects associated with other medicines administered as part of the treatment regimen for CASGEVY. Talk to your physician regarding those possible side effects. Your healthcare provider may give you other medicines to treat your side effects. How will I receive CASGEVY? Your healthcare provider will give you other medicines, including a conditioning medicine, as part of your treatment with CASGEVY. It’s important to talk to your healthcare provider about the risks and benefits of all medicines involved in your treatment. After receiving the conditioning medicine, it may not be possible for you to become pregnant or father a child. You should discuss options for fertility preservation with your healthcare provider before treatment. STEP 1: Before CASGEVY treatment, a doctor will give you mobilization medicine(s). This medicine moves blood stem cells from your bone marrow into the blood stream. The blood stem cells are then collected in a machine that separates the different blood cells (this is called apheresis). This entire process may happen more than once. Each time, it can take up to one week. During this step rescue cells are also collected and stored at the hospital. These are your existing blood stem cells and are kept untreated just in case there is a problem in the treatment process. If CASGEVY cannot be given after the conditioning medicine, or if the modified blood stem cells do not take hold (engraft) in the body, these rescue cells will be given back to you. If you are given rescue cells, you will not have any treatment benefit from CASGEVY. STEP 2: After they are collected, your blood stem cells will be sent to the manufacturing site where they are used to make CASGEVY. It may take up to 6 months from the time your cells are collected to manufacture and test CASGEVY before it is sent back to your healthcare provider. STEP 3: Shortly before your stem cell transplant, your healthcare provider will give you a conditioning medicine for a few days in hospital. This will prepare you for treatment by clearing cells from the bone marrow, so they can be replaced with the modified cells in CASGEVY. After you are given this medicine, your blood cell levels will fall to very low levels. You will stay in the hospital for this step and remain in the hospital until after the infusion with CASGEVY. STEP 4: One or more vials of CASGEVY will be given into a vein (intravenous infusion) over a short period of time. After the CASGEVY infusion, you will stay in hospital so that your healthcare provider can closely monitor your recovery. This can take 4-6 weeks, but times can vary. Your healthcare provider will decide when you can go home. What should I avoid after receiving CASGEVY? What are the possible or reasonably likely side effects of CASGEVY? The most common side effects of CASGEVY include: Your healthcare provider will test your blood to check for low levels of blood cells (including platelets and white blood cells). Tell your healthcare provider right away if you get any of the following symptoms: These are not all the possible side effects of CASGEVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of CASGEVY Talk to your healthcare provider about any health concerns. Please see full Prescribing Information including Patient Information for CASGEVY. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn , Facebook , Instagram , YouTube and X . (VRTX-GEN) Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Franco Locatelli, M.D., Ph.D. and Carmen Bozic, M.D., in this press release, and statements regarding expectations for the anticipated transformative, durable clinical benefits of CASGEVY, plans to continue working with reimbursement authorities to secure sustainable access for patients, including our expectations for progress in Canada and England, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com . You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. View source version on businesswire.com : https://www.businesswire.com/news/home/20241206536804/en/ CONTACT: Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.comMedia : mediainfo@vrtx.com or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS SOURCE: Vertex Pharmaceuticals Incorporated Copyright Business Wire 2024. PUB: 12/08/2024 12:52 PM/DISC: 12/08/2024 12:50 PM http://www.businesswire.com/news/home/20241206536804/enThree pro-BNP bodies march towards Indian mission
Spanish StandingsNone
AP Sports SummaryBrief at 2:50 p.m. EST
Police deny sitting on evidence as Netflix doc brings renewed attention to JonBenet Ramsey's killingUBA outperforms stocks with 375% returns in five yearsNew images of suspected UnitedHealthcare CEO killer released, but no answers on his identity or location They have seen him smiling on a hostel security camera, but don’t know his name. They found the backpack he discarded while fleeing, but don’t know where he’s gone. As the search for UnitedHealthcare CEO Brian Thompson’s killer goes on, investigators are reckoning with a tantalizing dichotomy: They have troves of evidence, but the shooter remains an enigma. Police don’t know who he is, where he is, or why he did it, though they are confident it was a targeted attack instead of a random act. “The net is tightening,” New York City Mayor Eric Adams said Saturday. Hours after he spoke, police divers were seen searching a pond in Central Park, where the killer fled after the shooting. Officers have been scouring the park for days for any possible clues and found his bag there Friday. Late Saturday, police released two additional photos of the suspected shooter that appeared to be from a camera mounted inside a taxi. The first shows him outside the vehicle and the second shows him looking through the partition between the back seat and the front of the cab. In both, his face is partially obscured by a blue, medical-style mask. Retracing the gunman’s steps using surveillance video, police say, it appears he left the city by bus soon after the shooting Wednesday morning outside the New York Hilton Midtown. He was seen on video at an uptown bus station about 45 minutes later, NYPD Chief of Detectives Joseph Kenny said. With the high-profile search expanding across state lines, the FBI announced late Friday that it was offering a $50,000 reward for information leading to an arrest and conviction, adding to a reward of up to $10,000 that the NYPD has offered. Police say they believe the suspect acted alone. Police provided no updates on the hunt Saturday, but investigators are urging patience — even with a killer on the loose. Hundreds of detectives are combing through video recordings and social media, vetting tips from the public and interviewing people who might have information, including Thompson’s family and coworkers and the shooter’s randomly assigned roommates at the Manhattan hostel where he stayed. “This isn’t ‘Blue Bloods.’ We’re not going to solve this in 60 minutes,” Kenny told reporters Friday. “We’re painstakingly going through every bit of evidence that we can come across.” The shooter paid cash at the hostel, presented what police believe was a fake ID and is believed to have paid cash for taxi rides and other transactions. He didn’t speak to others at the hostel and almost always kept his face covered with a mask, only lowering it while eating. But investigators caught a break when they came across security camera images of an unguarded moment in which he briefly showed his face soon after arriving in New York on Nov. 24. Police distributed the images to news outlets and on social media but so far haven’t been able to ID him using facial recognition — possibly because of the angle of the images or limitations on how the NYPD is allowed to use that technology, Kenny said. On Friday evening, investigators found a backpack in Central Park that had been worn by the gunman, police said. They didn’t immediately reveal what, if anything, it contained but said it would be tested and analyzed. Another potential clue, a fingerprint on an item he purchased at a Starbucks minutes before the shooting, has so far proven useless for identifying him, Kenny said. Aided by surveillance cameras on nearly every building and block, police have been able to retrace the shooter’s movements. They know he ambushed Thompson at 6:44 a.m. as the executive arrived at the Hilton for his company’s annual investor conference, using a 9 mm pistol that resembled the guns farmers use to put down animals without causing a loud noise. They know ammunition found near Thompson’s body bore the words “delay,” “deny” and “depose,” mimicking a phrase used by insurance industry critics. Kenny said the fact that the shooter knew UnitedHealthcare group was holding a conference at the hotel and what route Thompson might take to get there suggested that he could possibly be a disgruntled employee or client. Investigators know from surveillance video that the shooter fled into Central Park on a bicycle and ditched it around 7 a.m. near 85th Street. He then walked a couple blocks and got into a taxi, arriving at 7:30 a.m. at the George Washington Bridge Bus Station, which is near the northern tip of Manhattan and offers commuter service to New Jersey and Greyhound routes to Philadelphia, Boston and Washington. Investigators don’t know what happened next. They are searching through more surveillance video but have yet to locate video of the shooter getting on a bus or exiting the station. “We have reason to believe that the person in question has left New York City,” Police Commissioner Jessica Tisch told CNN on Friday. Police have determined from video that the gunman was in the city for 10 days before the shooting. He arrived at Manhattan’s main bus terminal on a Greyhound bus that originated in Atlanta, though it’s not clear whether he embarked there or at one of about a half-dozen stops along the route. Immediately after that, he took a cab to the vicinity of the Hilton and was there for about a half hour, Kenny said. At around 11 p.m. on the night he arrived, he went by taxi to the HI New York City Hostel. It was there, while speaking with an employee in the lobby, that he briefly pulled down the mask and smiled, giving investigators the brief glimpse they are now relying on to identify and capture a killer. — Associated Press writers Michael Balsamo in Washington, Jake Offenhartz, Cedar Attanasio and Karen Matthews in New York, John Seewer in Toledo, Ohio, and Jeff Martin in Atlanta contributed. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark nationalpost.com and sign up for our daily newsletter, Posted, here .
Retail Market in Indonesia to Expand by USD 49.56 Billion (2024-2028), Driven by Retail Growth and AI-Redefined Market Landscape - TechnavioMohamed Salah’s landmark goal pulls Liverpool clear in Champions LeagueBhubaneswar: Technology stopped tragedy from unfolding on the tracks. A herd of 28 elephants, including calves, were ambling along the Bandhamunda-Barsuan railway track in Rourkela, frequented by goods trains, when they were spotted by an artificial intelligence (AI)-based thermal camera. As soon as the camera picked up the movement of elephants, it sent inputs with location details and photographs to the control room of both the forest department and the railways. The railways was quick to act, delaying the movement of a goods train by 30 minutes to allow the elephants to cross the track. Forest officials said that at about 7 pm on Saturday, an AI camera detected the herd and took an image. "Within minutes of receiving the image and location, it was decided that the incoming train be delayed by half-an-hour at the nearest railway station at Lathikata. We coordinated with the railway as well to ensure that the elephants could cross the track before the train's arrival," said Jasobant Sethi, divisional forest officer, Rourkela. The elephants usually shuttle between Sana Parbat reserve forest and Tainsar under Panposh range in the Rourkela forest division. Sethi said the 360-degree movement of cameras also helped them detect elephants crossing over to the other side of the railway track safely, following which the train was passed the area. Till Dec last year, 36 elephants had died in train hits in a decade. The advent of technology is bound to help reduce such incidents. Prem Kumar Jha, principal chief conservator of forests (wildlife), said they had installed a 12-ft high tower atop which the high-resolution AI camera has been installed. "The camera has been installed at a strategic location. AI-based thermal cameras were first installed in Similipal Tiger Reserve, and their help led to the arrest of many poachers. We will install such sophisticated cameras at other places as well," said Jha. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword .
Jackson appeared to injure his neck while trying to tackle Missouri running back Jamal Roberts. Medical personnel tended to Jackson for approximately 10 minutes before he was placed on a backboard and driven to a waiting ambulance. Jackson gave a thumbs-up sign as he was carted off the snow-covered field. Arkansas athletic director Hunter Yurachek said Jackson had movement in his arms and legs but was experiencing pain in his neck. He said Jackson was taken to the hospital as a precaution. Jackson leads the Razorbacks with 9 1/2 tackles for loss and 6 1/2 sacks, and is considered a potential first-round pick in next year's NFL draft. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballPHILADELPHIA, PA — Vici has unveiled “ Proposal To Pitch ,” a new online platform designed to simplify and elevate the proposal process for media sales professionals and advertising agencies. The tool automates the creation of polished, interactive presentations, making it easier for users to respond to Requests for Proposals (RFPs) and stand out in a competitive market. With “Proposal To Pitch,” users can transform basic client details into dynamic online presentations that mirror the style of traditional PowerPoint decks but with interactive elements. By automating much of the RFP response process, the platform ensures faster turnaround and increased accuracy. Key features include automated content generation, integration of client branding and targeting details, and visual enhancements to showcase products like Social Mirror Ads, OTT, and Amazon Ads. The platform also provides forecasting tools to outline ad inventory predictions and budget implications, along with sales engagement data to track proposal performance. Features such as e-signature capabilities and automated follow-ups with drip email campaigns further streamline the sales process. “Proposal To Pitch is designed to empower teams with a fast, efficient, and visually appealing way to present their offerings,” said Todd Schumacher, CEO of Vici. “By streamlining the pitch process, we aim to help professionals achieve better client engagement and close more deals.” The platform is already receiving praise from industry users, including media organizations like Seven Mountains Media, which highlighted its ability to integrate digital, radio, and creative services into cohesive proposals. By combining technology and user-friendly design, “Proposal To Pitch” positions itself as a key solution for modernizing and optimizing media sales presentations. For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN .
COLUMBIA, Mo. (AP) — Arkansas defensive end Landon Jackson was carted off the field and taken to a hospital with a neck injury late in the first half of Saturday's game at No. 24 Missouri. Jackson appeared to injure his neck while trying to tackle Missouri running back Jamal Roberts. Medical personnel tended to Jackson for approximately 10 minutes before he was placed on a backboard and driven to a waiting ambulance. Jackson gave a thumbs-up sign as he was carted off the snow-covered field. Arkansas athletic director Hunter Yurachek said Jackson had movement in his arms and legs but was experiencing pain in his neck. He said Jackson was taken to the hospital as a precaution. Jackson leads the Razorbacks with 9 1/2 tackles for loss and 6 1/2 sacks, and is considered a potential first-round pick in next year's NFL draft. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
Manitoba government's promise to boost health care being questionedSalah nervelessly converted a 63rd-minute penalty, his 16th goal of the season, after French referee Benoit Bastien had been advised to take another look at Donny van de Beek’s clumsy challenge on Luis Diaz. In the process, he became just the 11th man to score 50 goals in the competition – Real Madrid’s Kylian Mbappe later also joined that exclusive club – on a night when victory at the Estadi Montilivi meant the six-time European champions will enter 2025 sitting proudly at the top of the table. ⭐️ A FIVE STAR PERFORMANCE ⭐️ #FCBayern #MiaSanMia | #SHAFCB #UCL pic.twitter.com/WELoxugaGn — FC Bayern (@FCBayernEN) December 10, 2024 France international Michael Olise produced a moment of magic to set the seal on Bayern Munich’s demolition of Shakhtar Donetsk and ease them towards the knockout stage. Olise’s brilliant stoppage-time run and finish capped a 5-1 victory for the Germans, in which he had early scored from the penalty spot, in Gelsenkirchen. Kevin’s fifth-minute strike had given the home side the perfect start, but Konrad Laimer levelled before Thomas Muller’s 55th goal in the competition sent the visitors in ahead at the break and set the stage for Olise’s double either side of Jamal Musiala’s strike. Jude Bellingham breathed life back into Real Madrid’s campaign as they held off Atalanta to earn a 3-2 victory in Bergamo. 🫲 @BellinghamJude 🫱 #UCL pic.twitter.com/jTynK04akR — Real Madrid C.F. 🇬🇧🇺🇸 (@realmadriden) December 10, 2024 After Charles De Ketelaere had cancelled out Mbappe’s opener from the penalty spot, second-half goals from Vinicius Junior and Bellingham in quick succession put the visitors in charge, although Ademola Lookman’s 65th-minute strike meant the contest was alive until the final whistle. Ross Barkley took Aston Villa a step closer to automatic qualification with a late winner against RB Leipzig in Germany. Villa had led twice through John McGinn and Jhon Duran, but equalisers from Lois Openda and Christoph Baumgartner kept Leipzig in it until substitute Barkley struck five minutes from time to snatch a 3-2 victory. Goals from Goncalo Ramos, Nuno Mendes and substitute Desire Doue – his first in the competition – handed French champions Paris St Germain a much-needed three points after a comfortable 3-0 win at RB Salzburg. He's making a list and checking it twiceB04 won and Nordi scored – nice! 🎅 pic.twitter.com/8bs6FGUaHz — Bayer 04 Leverkusen (@bayer04_en) December 10, 2024 Nordi Mukiele left it late to end Inter Milan’s unbeaten Champions League record as Bayer Leverkusen claimed a dramatic 1-0 victory at the BayArena. Mukiele struck in the 90th minute to inflict a first defeat across six games in this season’s competition on the Serie A champions – it was also the first goal they have conceded. Casper Nielsen came off the bench to fire Club Brugge to a 2-1 home victory over Sporting Lisbon after Eduardo Quaresma’s own goal had handed them a way back into the game following Geny Catamo’s early opener. Julien Le Cardinal’s first-half strike was enough to handed Brest a 1-0 victory over Eredivisie leaders PSV Eindhoven, while Kasper Schmeichel’s save from Marko Pjaca’s close-range 80th-minute header ensured Celtic returned from Dinamo Zagreb with a 0-0 draw.
Inside Alistair Johnston’s crazy career from live TV transfers to Dolly Parton’s hometown & signing new Celtic contract
General Motors Stock Is Rising After The Bell: What's Driving The Action?Review: The Anker Solix C300 rewrites the compact portable power station rule book
FBC GlanceSalah nervelessly converted a 63rd-minute penalty, his 16th goal of the season, after French referee Benoit Bastien had been advised to take another look at Donny van de Beek’s clumsy challenge on Luis Diaz. In the process, he became just the 11th man to score 50 goals in the competition – Real Madrid’s Kylian Mbappe later also joined that exclusive club – on a night when victory at the Estadi Montilivi meant the six-time European champions will enter 2025 sitting proudly at the top of the table. ⭐️ A FIVE STAR PERFORMANCE ⭐️ #FCBayern #MiaSanMia | #SHAFCB #UCL pic.twitter.com/WELoxugaGn — FC Bayern (@FCBayernEN) December 10, 2024 France international Michael Olise produced a moment of magic to set the seal on Bayern Munich’s demolition of Shakhtar Donetsk and ease them towards the knockout stage. Olise’s brilliant stoppage-time run and finish capped a 5-1 victory for the Germans, in which he had early scored from the penalty spot, in Gelsenkirchen. Kevin’s fifth-minute strike had given the home side the perfect start, but Konrad Laimer levelled before Thomas Muller’s 55th goal in the competition sent the visitors in ahead at the break and set the stage for Olise’s double either side of Jamal Musiala’s strike. Jude Bellingham breathed life back into Real Madrid’s campaign as they held off Atalanta to earn a 3-2 victory in Bergamo. 🫲 @BellinghamJude 🫱 #UCL pic.twitter.com/jTynK04akR — Real Madrid C.F. 🇬🇧🇺🇸 (@realmadriden) December 10, 2024 After Charles De Ketelaere had cancelled out Mbappe’s opener from the penalty spot, second-half goals from Vinicius Junior and Bellingham in quick succession put the visitors in charge, although Ademola Lookman’s 65th-minute strike meant the contest was alive until the final whistle. Ross Barkley took Aston Villa a step closer to automatic qualification with a late winner against RB Leipzig in Germany. Villa had led twice through John McGinn and Jhon Duran, but equalisers from Lois Openda and Christoph Baumgartner kept Leipzig in it until substitute Barkley struck five minutes from time to snatch a 3-2 victory. Goals from Goncalo Ramos, Nuno Mendes and substitute Desire Doue – his first in the competition – handed French champions Paris St Germain a much-needed three points after a comfortable 3-0 win at RB Salzburg. He's making a list and checking it twiceB04 won and Nordi scored – nice! 🎅 pic.twitter.com/8bs6FGUaHz — Bayer 04 Leverkusen (@bayer04_en) December 10, 2024 Nordi Mukiele left it late to end Inter Milan’s unbeaten Champions League record as Bayer Leverkusen claimed a dramatic 1-0 victory at the BayArena. Mukiele struck in the 90th minute to inflict a first defeat across six games in this season’s competition on the Serie A champions – it was also the first goal they have conceded. Casper Nielsen came off the bench to fire Club Brugge to a 2-1 home victory over Sporting Lisbon after Eduardo Quaresma’s own goal had handed them a way back into the game following Geny Catamo’s early opener. Julien Le Cardinal’s first-half strike was enough to handed Brest a 1-0 victory over Eredivisie leaders PSV Eindhoven, while Kasper Schmeichel’s save from Marko Pjaca’s close-range 80th-minute header ensured Celtic returned from Dinamo Zagreb with a 0-0 draw.Biden calls for Assad to be 'held accountable'
online gambling examples
online casino 247 register